As of June 15, 2025, Eli Lilly and Co (LLY) reports a Forward P/E of 37.15.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Eli Lilly and Co's Forward P/E to Peers
To better understand Eli Lilly and Co's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Eli Lilly and Co (LLY) | 37.15 |
| Catalent Inc (CTLT) | 55.81 |
| Corcept Therapeutics Inc (CORT) | 49.38 |
| Innoviva Inc (INVA) | 32.05 |
| Zoetis Inc (ZTS) | 25.65 |
| Horizon Therapeutics PLC (HZNP) | 25.39 |
Compared to its competitors, Eli Lilly and Co's Forward P/E is among the highest compared to peers, reflecting higher growth expectations from investors.